Metformin for endometrial hyperplasia: a Cochrane protocol

about

Progestin Intrauterine Devices and Metformin: Endometrial Hyperplasia and Early Stage Endometrial Cancer Medical Management.

P2860

Q41665625-28E51D6F-FC76-4C05-9FA5-0958673CE91F

P2860

Metformin for endometrial hyperplasia: a Cochrane protocol

Item

http://www.wikidata.org/entity/Q36105494

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Metformin for endometrial hyperplasia: a Cochrane protocol

@ast

Metformin for endometrial hyperplasia: a Cochrane protocol

@en

type

Item

label

Metformin for endometrial hyperplasia: a Cochrane protocol

@ast

Metformin for endometrial hyperplasia: a Cochrane protocol

@en

prefLabel

Metformin for endometrial hyperplasia: a Cochrane protocol

@ast

Metformin for endometrial hyperplasia: a Cochrane protocol

@en

P1476

Metformin for endometrial hyperplasia: a Cochrane protocol

@en

P2093

Caroline A Mulvaney

http://www.w3.org/2001/XMLSchema#string

Hunain Shiwani

http://www.w3.org/2001/XMLSchema#string

Juliane R F Saner

http://www.w3.org/2001/XMLSchema#string

Naomi S Clement

http://www.w3.org/2001/XMLSchema#string

Thomas R W Oliver

http://www.w3.org/2001/XMLSchema#string

P2860

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial

Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome

Measuring inconsistency in meta-analyses

The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients

Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia.

Progesterone: the ultimate endometrial tumor suppressor.

Understanding the benefit of metformin use in cancer treatment.

Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.

P304

e013385

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJOPEN-2016-013385

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

William Atiomo

P577

2016-08-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27531741

http://www.w3.org/2001/XMLSchema#string

P921

metformin

P932

5013431

http://www.w3.org/2001/XMLSchema#string

Metformin for endometrial hyperplasia: a Cochrane protocol

about

P2860

P2860

Metformin for endometrial hyperplasia: a Cochrane protocol

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932